Navigation Links
Vanda Pharmaceuticals Provides Update on Iloperidone
Date:9/11/2008

arly stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended June 30, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
2. Vanda Presents Phase III Iloperidone Efficacy Data
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
5. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
6. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
7. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
8. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
9. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
10. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
11. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Inivata, a Cambridge, England -based ... the 2015 American Association for Cancer Research (AACR) Annual Meeting ... and a poster presentation. Michael Stocum , CEO ... nd . The presentation, entitled Monitoring the ... part of a session on Recent Advances in Diagnostics ...
(Date:4/17/2015)... and Markets ( http://www.researchandmarkets.com/research/lmsnqn/medical_equipment ) has announced ... Leasing - Global Strategic Business Report" report to ... markets for Medical Equipment Rental and Leasing in US$ ... US, Japan , Europe ... estimates and forecasts are provided for the period 2014 ...
(Date:4/17/2015)... 2015  Trovagene, Inc., (NASDAQ:  TROV) a developer ... data presented at the 2015 European Lung Cancer ... Monitoring ℠ (PCM) platform outperformed tissue biopsy ... T790M mutations in metastatic lung cancer patients. ... Mutation in Urinary Circulating Tumor DNA from Metastatic ...
Breaking Medicine Technology:Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2Medical Equipment Rental and Leasing Market 2015-2020 - Global Strategic Business Report - Healthcare Spending Slowdown Bodes Well for Medical Equipment Leasing 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4
... 18 Novavax, Inc. (Nasdaq: NVAX ) a ... , President and Chief Executive Officer, will be presenting at ... 21 and June 22, 2010 at The ... in the roundtable discussion, , Getting ready for the next ...
... , June 17 Allied Healthcare Products, Inc. (Nasdaq: ... carbon dioxide absorbent that provides enhanced patient safety over conventional absorbents ... , ... commonly associated with conventional carbon dioxide absorbents, yet it has been ...
Cached Medicine Technology:Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2010 2Allied Healthcare Announces Litholyme(TM) -- New CO2 Absorbent Used in Anesthesia 2
(Date:4/18/2015)... April 18, 2015 In the past ... couple of changes. , "We had to run maintenance ... needed changes," said Jennifer Ramirez, the PR Director. "It ... to say that we are back on track after ... the process of changing phone systems which has not ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 On April 14th, ... Threat Report , which they say, “exposes a tactical shift ... new malware variants were introduced in 2014 - almost a ... Zero Day threats to be identified and patched by prominent ... abundantly clear that doing business in a digital world can ...
(Date:4/18/2015)... 2015 “ ArcAngel ” was featured on ... look at the latest and coolest applications on ... host of AppWatch and technology expert, conducted the app review ... app. , In a turbulent world, people may find ... should always be their first move, but some situations can ...
(Date:4/18/2015)... French physician and gastronome Anthelme Brillat-Savarin ... he uttered, “Tell me what you eat, and I ... cope with stress or sadness has often been attributed ... otherwise. Data collected from their Emotional Eating Test ... eating, but for different reasons. , Collecting data from ...
(Date:4/17/2015)... John Evans, a Gardant affordable assisted ... from 2 p.m. to 3 p.m. on April 24. ... Ct. in Pekin, Illinois, serves older adults of all ... to maintain their independence. , Becky Baker will entertain ... be served during the luau. , For more information, ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Temporary Number Available 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 2Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 3Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 4Health News:Cyber Attackers Continue to Fine Tune Deception and Stealth Tactics According to New Report 5Health News:A Personal Safety Application was Featured on NewsWatch Television 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 2Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 3Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 4Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 5Health News:It’s Not Just A Girl Thing: Queendom Study Reveals That Men Struggle With Emotional Eating Too 6Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2
... June 27, HIV Testing Day, the HIV Medicine Association (HIVMA) ... in linking people to lifesaving care and reducing the spread ... HIVMA calls on policymakers to do more to make every ... covers such screening as a standard part of routine medical ...
... 22 Epeius Biotechnologies ( www.epeiusbiotech.com ) ... demonstration of single-agent efficacy with its lead product, Rexin-G, ... of June 16, 2009 in Molecular Therapy, the Official ... www.nature.com/mt/ ) documents the results of two ...
... Lead Educational Underwriter , , WASHINGTON, June 22 ... Innovation and Technology Congress (WHIT 5.0), in conjunction with ... announces that President Bill Clinton will deliver a keynote ... 2009. , , President Clinton will join ...
... D.C., June 23, 2009 With millions of people in ... and our Canadian neighbors doing likewise for their July ... light shows of the future likely to ignite a smile ... fireworks is quietly making its way toward the sky. ...
... MapHIV.org Shows Vast Majority of Nation,s HIV Burden Clustered in ... The National Minority Quality Forum ... highlights the impact of the HIV/AIDS epidemic in communities across ... rates available in a single location for the first time, ...
... National Minority Quality Forum Launches First U.S. HIV/AIDS Atlas , ... Minority Quality Forum today launched a groundbreaking HIV/AIDS Atlas ( ... of the HIV/AIDS epidemic in communities across the United States. ... in a single location for the first time, painting a ...
Cached Medicine News:Health News:On HIV Testing Day, HIVMA calls for health care reform to make testing routine every day 2Health News:Clinical Studies Validate Cancer Gene Delivery Platform: Landmark Publication Confirms Rexin-G Effectively Targets Metastatic Cancers and Improves Patient Survival 2Health News:President Bill Clinton to Deliver Keynote Address at 5th Annual World Healthcare Innovation and Technology Congress, November 10, 2009, Washington, D.C. 2Health News:President Bill Clinton to Deliver Keynote Address at 5th Annual World Healthcare Innovation and Technology Congress, November 10, 2009, Washington, D.C. 3Health News:'Green' fireworks may brighten eco-friendly 4th of July displays in future 2Health News:Video: National Minority Quality Forum Launches First U.S. HIV/AIDS Atlas 2Health News:Video: National Minority Quality Forum Launches First U.S. HIV/AIDS Atlas 3Health News:MapHIV.org Shows Massachusetts' Suffolk County Seriously Impacted by HIV and AIDS 2Health News:MapHIV.org Shows Massachusetts' Suffolk County Seriously Impacted by HIV and AIDS 3
Enzyme Immunoassay for the quantitative ( qualitative 0020, on request) determination of IgG Class antibodies to Rubella virus....
Donor Screen & Confirmation Kit...
... antibody gives positive staining of prostatic ... hyperplasia. In cases of prostatic cancer, ... give definite but weak staining or ... cells; this pattern of staining permits ...
... a comprehensive line of pregnancy tests including ... in convenient one-step stick and cassette formats. ... Clearview Easy HCG is a 25 mIU ... Clearview HCG II provides 25mIU sensitivity ...
Medicine Products: